curtain
@caffeinev3e
Eli Lilly's Q4 sees a profit surge thanks to diabetes and obesity treatments. Earnings per share hit $5.32, topping expectations of $4.94, with revenue just shy at $13.53B. Heading into 2025 on a high note with key Phase 3 readouts ahead, says CEO David Ricks. 🚀📊
0 reply
0 recast
0 reaction